W3BCLOUD
25.6.2020 12:02:09 CEST | Business Wire | Press release
W3BCLOUD , a joint venture between Advanced Micro Devices (NASDAQ: AMD) and ConsenSys, announced today that it has completed its initial close of $20.5M in convertible notes from Advanced Micro Devices (NASDAQ: AMD) and ConsenSys, along with several family offices in the United Arab Emirates. With this first round of funding, W3BCLOUD will ramp and operate its first Ethereum blockchain data centers. W3BCLOUD will expand its network of decentralized data centers across the globe as more funding is raised.
Ethereum is emerging as the programmable blockchain of choice for decentralized finance (DeFi) and United States Dollar-pegged stablecoins. The economic dislocation of 2020 coupled with the global dollar shortage sparked a significant increase in dollar-backed stablecoins transactions on the Ethereum blockchain.
“The trustless, permissionless and decentralized economy requires robust and dedicated data centers to scale. W3BCLOUD brings together the pre-eminent GPU manufacturer and the leading blockchain developer to build the compute infrastructure for the blockchain economy,” said Co-Founder and CEO Sami Issa.
Post economic recovery, individuals, enterprises and governments will prioritize resilience and resiliency requires geopolitical decentralization, permissionless and robust infrastructure.
"W3BCLOUD is building the next generation decentralized compute, storage and bandwidth for the planet," said Ethereum Co-Creator and ConsenSys Founder, Joseph Lubin.
“Parallel and Distributed Computing focused on blockchain use cases is a fast-growing segment of the industry. I am very excited to see W3BCLOUD power up their first GPU-centric data center focused on blockchain as they work to ramp aggressively across multiple geographies throughout 2020,” says Jörg Roskowetz, Head of Blockchain Business Unit, AMD.
About W3BCLOUD
W3BCLOUD is an exclusive joint venture between Advanced Micro Devices (NASDAQ:AMD), a leading high-performance computing, graphics and visualization technologies company, and ConsenSys, the leading blockchain software development and product company. W3BCLOUD is building a global network of high-performance data centers to enable Web 3.0 and the blockchain economy. The team has 100+ years of global experience in Semiconductors, Data Centers, Blockchain, Crypto, Cloud and AI. W3BCLOUD is headquartered in Dublin, Ireland.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005351/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom